Universal Beteiligungs und Servicegesellschaft mbH Acquires Shares of 121,776 Collegium Pharmaceutical, Inc. (NASDAQ:COLL)

Universal Beteiligungs und Servicegesellschaft mbH acquired a new stake in shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL - Free Report) during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor acquired 121,776 shares of the specialty pharmaceutical company's stock, valued at approximately $3,489,000. Universal Beteiligungs und Servicegesellschaft mbH owned approximately 0.38% of Collegium Pharmaceutical as of its most recent SEC filing.

A number of other large investors also recently modified their holdings of COLL. New Age Alpha Advisors LLC bought a new stake in shares of Collegium Pharmaceutical during the 4th quarter valued at about $40,000. KBC Group NV boosted its stake in Collegium Pharmaceutical by 72.5% in the fourth quarter. KBC Group NV now owns 2,336 shares of the specialty pharmaceutical company's stock valued at $67,000 after acquiring an additional 982 shares during the period. Virtus Fund Advisers LLC grew its holdings in shares of Collegium Pharmaceutical by 30.5% during the fourth quarter. Virtus Fund Advisers LLC now owns 2,419 shares of the specialty pharmaceutical company's stock valued at $69,000 after purchasing an additional 565 shares during the last quarter. China Universal Asset Management Co. Ltd. raised its position in shares of Collegium Pharmaceutical by 10.4% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 6,838 shares of the specialty pharmaceutical company's stock worth $196,000 after purchasing an additional 642 shares during the period. Finally, FORA Capital LLC bought a new stake in shares of Collegium Pharmaceutical in the 4th quarter worth approximately $223,000.

Insider Buying and Selling

In other news, EVP Shirley R. Kuhlmann sold 26,067 shares of the business's stock in a transaction that occurred on Thursday, March 6th. The shares were sold at an average price of $28.50, for a total transaction of $742,909.50. Following the sale, the executive vice president now owns 108,137 shares in the company, valued at $3,081,904.50. The trade was a 19.42% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Scott Dreyer sold 2,255 shares of Collegium Pharmaceutical stock in a transaction that occurred on Friday, March 14th. The stock was sold at an average price of $30.00, for a total transaction of $67,650.00. Following the transaction, the executive vice president now owns 124,421 shares in the company, valued at approximately $3,732,630. The trade was a 1.78% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 41,693 shares of company stock worth $1,211,794 in the last three months. 2.51% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

COLL has been the topic of several analyst reports. Piper Sandler reaffirmed a "neutral" rating and issued a $37.00 target price (up from $36.00) on shares of Collegium Pharmaceutical in a research report on Friday, May 9th. HC Wainwright reissued a "buy" rating and issued a $50.00 price objective on shares of Collegium Pharmaceutical in a report on Monday, March 24th. Wall Street Zen downgraded Collegium Pharmaceutical from a "strong-buy" rating to a "buy" rating in a research note on Saturday, April 19th. Finally, Needham & Company LLC reiterated a "buy" rating and set a $46.00 price target on shares of Collegium Pharmaceutical in a research report on Wednesday, April 9th. One analyst has rated the stock with a hold rating and five have issued a buy rating to the stock. According to MarketBeat, Collegium Pharmaceutical currently has an average rating of "Moderate Buy" and a consensus price target of $43.80.

Collegium Pharmaceutical Price Performance

Shares of COLL stock traded down $0.08 during mid-day trading on Tuesday, hitting $29.23. 323,265 shares of the stock traded hands, compared to its average volume of 421,485. Collegium Pharmaceutical, Inc. has a twelve month low of $23.23 and a twelve month high of $42.29. The company has a debt-to-equity ratio of 3.43, a quick ratio of 0.88 and a current ratio of 0.97. The company's 50-day simple moving average is $28.00 and its 200-day simple moving average is $29.60. The firm has a market cap of $939.22 million, a price-to-earnings ratio of 12.60 and a beta of 0.63.

Collegium Pharmaceutical (NASDAQ:COLL - Get Free Report) last released its earnings results on Thursday, May 8th. The specialty pharmaceutical company reported $1.49 EPS for the quarter, missing the consensus estimate of $1.50 by ($0.01). The business had revenue of $177.76 million for the quarter, compared to analyst estimates of $174.96 million. Collegium Pharmaceutical had a net margin of 14.78% and a return on equity of 104.67%. The firm's revenue for the quarter was up 22.7% on a year-over-year basis. During the same period in the prior year, the company earned $1.45 earnings per share. As a group, equities research analysts expect that Collegium Pharmaceutical, Inc. will post 5.62 earnings per share for the current year.

Collegium Pharmaceutical Profile

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.